Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
Submitted by
admin
on October 8, 2018 - 9:55am
Source:
CP Wire
News Tags:
Exelixis
Cabometyx
thyroid cancer
Headline:
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
snippet:
Thyroid cancer is the most rapidly increasing cancer diagnosis in the US with incidence tripling over the last 30 years
Cabometyx is approved for renal cell carcinoma and hepatocellular carcinoma
It has orphan drug status in the US for advanced hepatocellular carcinoma
Do Not Allow Advertisers to Use My Personal information
